JP2023513502A5 - - Google Patents
Info
- Publication number
- JP2023513502A5 JP2023513502A5 JP2022547273A JP2022547273A JP2023513502A5 JP 2023513502 A5 JP2023513502 A5 JP 2023513502A5 JP 2022547273 A JP2022547273 A JP 2022547273A JP 2022547273 A JP2022547273 A JP 2022547273A JP 2023513502 A5 JP2023513502 A5 JP 2023513502A5
- Authority
- JP
- Japan
- Prior art keywords
- purified rna
- composition according
- rna
- purified
- lipid components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025260641A JP2026048878A (ja) | 2020-02-04 | 2025-12-17 | コロナウイルスワクチン |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020052775 | 2020-02-04 | ||
| EPPCT/EP2020/052775 | 2020-02-04 | ||
| EP2020059687 | 2020-04-03 | ||
| EPPCT/EP2020/059687 | 2020-04-03 | ||
| EP2020065091 | 2020-05-29 | ||
| EPPCT/EP2020/065091 | 2020-05-29 | ||
| EPPCT/EP2020/079831 | 2020-10-22 | ||
| EP2020079831 | 2020-10-22 | ||
| EP2020079973 | 2020-10-23 | ||
| EPPCT/EP2020/079973 | 2020-10-23 | ||
| EP2020080713 | 2020-11-02 | ||
| EPPCT/EP2020/080713 | 2020-11-02 | ||
| US202063112106P | 2020-11-10 | 2020-11-10 | |
| US63/112,106 | 2020-11-10 | ||
| US202063113159P | 2020-11-12 | 2020-11-12 | |
| US63/113,159 | 2020-11-12 | ||
| US202063119390P | 2020-11-30 | 2020-11-30 | |
| US63/119,390 | 2020-11-30 | ||
| US202063129395P | 2020-12-22 | 2020-12-22 | |
| US63/129,395 | 2020-12-22 | ||
| PCT/EP2021/052455 WO2021156267A1 (en) | 2020-02-04 | 2021-02-03 | Coronavirus vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260641A Division JP2026048878A (ja) | 2020-02-04 | 2025-12-17 | コロナウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513502A JP2023513502A (ja) | 2023-03-31 |
| JP2023513502A5 true JP2023513502A5 (https=) | 2024-02-13 |
| JP7793525B2 JP7793525B2 (ja) | 2026-01-05 |
Family
ID=74586987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547273A Active JP7793525B2 (ja) | 2020-02-04 | 2021-02-03 | コロナウイルスワクチン |
| JP2025260641A Pending JP2026048878A (ja) | 2020-02-04 | 2025-12-17 | コロナウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025260641A Pending JP2026048878A (ja) | 2020-02-04 | 2025-12-17 | コロナウイルスワクチン |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP4147717A1 (https=) |
| JP (2) | JP7793525B2 (https=) |
| KR (1) | KR20220144416A (https=) |
| CN (1) | CN116113430A (https=) |
| AU (1) | AU2021216658A1 (https=) |
| BR (1) | BR112022014627A2 (https=) |
| CA (1) | CA3160511A1 (https=) |
| DE (4) | DE202021003575U1 (https=) |
| ES (1) | ES3053772T1 (https=) |
| IL (3) | IL314906B2 (https=) |
| MX (1) | MX2022009460A (https=) |
| TW (1) | TW202140518A (https=) |
| WO (1) | WO2021156267A1 (https=) |
| ZA (1) | ZA202406805B (https=) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| IL298362A (en) * | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus antigen compositions and their uses |
| CA3170740A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| AU2021293780A1 (en) | 2020-06-19 | 2023-02-02 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
| WO2022016122A2 (en) * | 2020-07-17 | 2022-01-20 | Tonix Pharmaceuticals Holding Corp. | Skin-based testing for detection of cell-mediated immune responses to sars-cov-2 |
| WO2022046583A1 (en) * | 2020-08-24 | 2022-03-03 | Phylex Biosciences, Inc. | Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (sars) coronavirus infection |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| EP4262864A4 (en) * | 2020-12-18 | 2025-06-04 | The Scripps Research Institute | IMMUNOGENIC COMPOSITIONS |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| WO2022155524A1 (en) * | 2021-01-15 | 2022-07-21 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| JP2024503699A (ja) * | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | バリアント株ベースのコロナウイルスワクチン |
| JP2024503482A (ja) * | 2021-01-15 | 2024-01-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 複製可能アデノウイルス４型ｓａｒｓ－ｃｏｖ－２ワクチンおよびそれらの使用 |
| CA3171429A1 (en) | 2021-03-31 | 2022-09-30 | Alexander SCHWENGER | Syringes containing pharmaceutical compositions comprising rna |
| CN113150085B (zh) * | 2021-04-27 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的组合物 |
| WO2023015332A1 (en) * | 2021-08-11 | 2023-02-16 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Vaccine antigen |
| WO2023018384A1 (en) * | 2021-08-13 | 2023-02-16 | Chulalongkorn University | A vaccine composition against coronavirus infection |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025031A1 (zh) * | 2021-08-23 | 2023-03-02 | 北京百普赛斯生物科技股份有限公司 | 用于疫苗或中和抗体测试中的SARS-CoV-2病毒S蛋白中和表位 |
| CN115710191B (zh) * | 2021-08-23 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| CN115710193B (zh) * | 2021-08-23 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| TWI844087B (zh) * | 2021-09-02 | 2024-06-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2)變異株之免疫組合物及方法 |
| US20240398933A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20240385189A1 (en) * | 2021-09-10 | 2024-11-21 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| CN113896774B (zh) * | 2021-09-18 | 2023-07-28 | 中国医学科学院医学生物学研究所 | 一种重组蛋白k-s及其制备方法和应用 |
| CN115850686B (zh) * | 2021-09-27 | 2026-01-30 | 广州谷森制药有限公司 | 新型氘代聚乙二醇脂质化合物 |
| CA3132191A1 (en) * | 2021-09-28 | 2023-03-28 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
| US20260041759A1 (en) * | 2021-10-01 | 2026-02-12 | Board Of Regents, The University Of Texas System | COVID19 mRNA Vaccine |
| WO2023057444A1 (en) * | 2021-10-05 | 2023-04-13 | Sanofi | METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME |
| AU2022358982A1 (en) * | 2021-10-06 | 2024-05-23 | Diosynvax Ltd | Coronavirus vaccines |
| KR20230053998A (ko) * | 2021-10-15 | 2023-04-24 | (주)지노믹트리 | mRNA 발현을 위한 유전자 구조체 |
| WO2023064907A1 (en) * | 2021-10-15 | 2023-04-20 | Yale University | Compositions and methods for vaccination against pathogenic coronavirus species and variants |
| EP4419136A1 (en) * | 2021-10-21 | 2024-08-28 | BioNTech SE | Coronavirus vaccine |
| WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
| EP4183409A1 (en) * | 2021-11-17 | 2023-05-24 | Charité - Universitätsmedizin Berlin | Vaccine with improved immunogenicity against mutant coronaviruses |
| EP4436984A1 (en) * | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| CN118401544A (zh) * | 2021-11-24 | 2024-07-26 | 旗舰创业创新六公司 | 水痘-带状疱疹病毒免疫原组合物及其用途 |
| IL312965A (en) * | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20230095025A (ko) * | 2021-12-20 | 2023-06-28 | 아이진 주식회사 | 변이 SARS-CoV-2 백신 조성물 및 이의 용도 |
| RU2769224C1 (ru) * | 2021-12-30 | 2022-03-29 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Рекомбинантные вирусоподобные частицы для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 |
| GB202119115D0 (en) * | 2021-12-30 | 2022-02-16 | Fondo Ricerca Medica S R I | Vaccine |
| WO2023133684A1 (en) * | 2022-01-11 | 2023-07-20 | Peking University | Circular rna vaccines against sars-cov-2 variants and methods of use thereof |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116731192A (zh) * | 2022-03-01 | 2023-09-12 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
| EP4486375A1 (en) * | 2022-03-02 | 2025-01-08 | ISR Immune System Regulation Holding AB (publ) | Vaccine composition comprising an antigen and a tlr3 agonist |
| CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
| CA3251095A1 (en) * | 2022-04-29 | 2023-11-02 | Yale University | IMMUNITY BOOSTING METHOD |
| CN119563028A (zh) * | 2022-05-12 | 2025-03-04 | 尚威天成信使核糖核酸治疗公司 | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| WO2024014770A1 (ko) * | 2022-07-14 | 2024-01-18 | 엠큐렉스 주식회사 | mRNA 백신 및 치료제의 제조를 위한 변형된 RNA |
| US11898186B1 (en) * | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| CN116621990B (zh) * | 2022-09-06 | 2024-01-02 | 广东药科大学 | 一种SARS-CoV-2疫苗抗原的制备方法及其应用 |
| AU2023353931A1 (en) | 2022-09-26 | 2025-03-20 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024073848A1 (en) * | 2022-10-04 | 2024-04-11 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| CN116240223A (zh) * | 2022-12-13 | 2023-06-09 | 浙江大学 | 一种复制型mRNA疫苗及其制备方法 |
| EP4652284A1 (en) * | 2023-01-20 | 2025-11-26 | Astrazeneca AB | Vaccine |
| EP4669348A1 (en) * | 2023-02-24 | 2025-12-31 | BioNTech SE | IMMUNOGENEOUS COMPOSITIONS |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| AU2024260120A1 (en) | 2023-04-27 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024222737A1 (zh) * | 2023-04-28 | 2024-10-31 | 北京先声祥瑞生物制品股份有限公司 | 工程化的mRNA及其用途 |
| WO2024235231A1 (en) * | 2023-05-15 | 2024-11-21 | Providence Therapeutics Holdings Inc. | Compositions and methods for the prevention and/or treatment of covid-19 |
| CN121568708A (zh) | 2023-05-26 | 2026-02-24 | 库瑞瓦格欧洲股份公司 | 癌症抗原 |
| KR102878618B1 (ko) * | 2023-06-08 | 2025-10-30 | 한림대학교 산학협력단 | 사스코로나바이러스-2 변이체에 대한 에피토프 펩타이드 및 이를 포함하는 사스코로나바이러스-2 변이체에 대한 백신 후보 조성물 |
| WO2024260570A1 (en) | 2023-06-23 | 2024-12-26 | CureVac SE | Nucleic acid encoded antibodies |
| AU2024301594A1 (en) * | 2023-07-26 | 2026-01-08 | Cadmus Animal Health Limited | Rna vaccines for use in animal health |
| WO2025019901A1 (en) * | 2023-07-26 | 2025-01-30 | Denteric Pty Ltd | Rna vaccines |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| CN117224662B (zh) * | 2023-08-24 | 2025-05-16 | 北京悦康科创医药科技股份有限公司 | 测定多价新冠mRNA疫苗各组分含量的方法 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| CN117253577B (zh) * | 2023-11-17 | 2024-03-12 | 四川省大数据技术服务中心 | 一种多维卫生健康数据集成处理系统 |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR702E (fr) | 1903-02-28 | Caille Charles | Appareil stérilisateur pour l'eau ou d'autres liquides | |
| US2780312A (en) | 1953-11-30 | 1957-02-05 | Daniel I Glossbrenner | Electro-mechanical lubricant distributor |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| MXPA05004860A (es) | 2002-11-04 | 2005-08-18 | Advisys Inc | Promotores musculares sinteticos con actividades que exceden las secuencias reguladoras de origen natural en las celulas cardiacas. |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| EP1809753A1 (en) | 2004-11-02 | 2007-07-25 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| US9371533B2 (en) | 2008-06-12 | 2016-06-21 | Expres2Ion Biotechnologies Aps | Protein expression system |
| WO2010021865A1 (en) | 2008-08-18 | 2010-02-25 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2809858C (en) | 2010-09-20 | 2019-11-12 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CA2811430A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| JP6182457B2 (ja) | 2011-12-12 | 2017-08-16 | 協和発酵キリン株式会社 | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 |
| WO2013143700A2 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
| ES2708562T3 (es) | 2013-03-14 | 2019-04-10 | Translate Bio Inc | Evaluación cuantitativa de la eficacidad de tapa de ARN mensajero |
| ES3032935T3 (en) | 2013-10-22 | 2025-07-29 | Translate Bio Inc | Lipid formulations for delivery of messenger rna |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| EP3155129B1 (en) | 2014-06-10 | 2019-01-16 | CureVac AG | Method for enhancing rna production |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| US20180085391A1 (en) | 2014-08-08 | 2018-03-29 | Modernatx, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
| US9620868B2 (en) | 2014-10-27 | 2017-04-11 | Matthew Wootton | Compact electrical connection system |
| PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
| EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
| EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP4026568A1 (en) | 2015-04-17 | 2022-07-13 | CureVac Real Estate GmbH | Lyophilization of rna |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
| WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
| EP4660315A3 (en) | 2015-05-29 | 2026-03-18 | CureVac Manufacturing GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| WO2017036580A1 (en) | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
| CN120842296A (zh) | 2015-09-21 | 2025-10-28 | 垂林克生物技术有限公司 | 用于合成5’-加帽rna的组合物和方法 |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| SI3362461T1 (sl) | 2015-10-16 | 2022-05-31 | Modernatx, Inc. | Analogi kape MRNA z modificirano fosfatno povezavo |
| WO2017066793A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP7384512B2 (ja) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| US9834510B2 (en) | 2015-12-30 | 2017-12-05 | Arcturus Therapeutics, Inc. | Aromatic ionizable cationic lipid |
| EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
| US20190336611A1 (en) | 2016-06-09 | 2019-11-07 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| CN109475640B (zh) | 2016-06-09 | 2023-03-10 | 库瑞瓦格欧洲公司 | 核酸被运载物的混合载运体 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CA3040337A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| US20220233568A1 (en) | 2017-10-19 | 2022-07-28 | Curevac Ag | Novel artificial nucleic acid molecules |
| US11964051B2 (en) | 2018-05-16 | 2024-04-23 | Translate Bio, Inc. | Ribose cationic lipids |
| JP7488193B2 (ja) | 2018-05-24 | 2024-05-21 | トランスレイト バイオ， インコーポレイテッド | チオエステルカチオン性脂質 |
| US12240824B2 (en) | 2018-05-30 | 2025-03-04 | Translate Bio, Inc. | Vitamin cationic lipids |
| WO2019232208A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
| CA3101484A1 (en) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Phosphoester cationic lipids |
| WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| CN109787464B (zh) | 2019-03-27 | 2022-07-12 | 阳光电源股份有限公司 | 一种拓扑单元并联保护方法、装置及系统 |
| JP2023511633A (ja) | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
-
2021
- 2021-02-03 KR KR1020227028435A patent/KR20220144416A/ko active Pending
- 2021-02-03 MX MX2022009460A patent/MX2022009460A/es unknown
- 2021-02-03 CA CA3160511A patent/CA3160511A1/en active Pending
- 2021-02-03 JP JP2022547273A patent/JP7793525B2/ja active Active
- 2021-02-03 EP EP22191103.5A patent/EP4147717A1/en not_active Withdrawn
- 2021-02-03 IL IL314906A patent/IL314906B2/en unknown
- 2021-02-03 TW TW110104048A patent/TW202140518A/zh unknown
- 2021-02-03 WO PCT/EP2021/052455 patent/WO2021156267A1/en not_active Ceased
- 2021-02-03 DE DE202021003575.3U patent/DE202021003575U1/de not_active Withdrawn - After Issue
- 2021-02-03 ES ES21704439T patent/ES3053772T1/es active Pending
- 2021-02-03 CN CN202180010211.1A patent/CN116113430A/zh active Pending
- 2021-02-03 DE DE112021000012.8T patent/DE112021000012C9/de active Active
- 2021-02-03 DE DE202021004123.0U patent/DE202021004123U1/de not_active Withdrawn - After Issue
- 2021-02-03 EP EP21704439.5A patent/EP3886897A1/en active Pending
- 2021-02-03 IL IL293571A patent/IL293571B2/en unknown
- 2021-02-03 AU AU2021216658A patent/AU2021216658A1/en active Pending
- 2021-02-03 DE DE202021004130.3U patent/DE202021004130U1/de active Active
- 2021-02-03 BR BR112022014627A patent/BR112022014627A2/pt unknown
-
2024
- 2024-09-04 ZA ZA2024/06805A patent/ZA202406805B/en unknown
-
2025
- 2025-10-29 IL IL324312A patent/IL324312A/en unknown
- 2025-12-17 JP JP2025260641A patent/JP2026048878A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513502A5 (https=) | ||
| JP2024502210A5 (https=) | ||
| JP2022136230A5 (https=) | ||
| JP2024514183A (ja) | エプスタイン－バーウイルスｍＲＮＡワクチン | |
| ES3053772T1 (en) | Coronavirus vaccine | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| JP2014518612A5 (https=) | ||
| JP2021534798A5 (https=) | ||
| JP2024531486A (ja) | 環状ｒｎａを調製するための構築物及び方法 | |
| US10023862B2 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2025073123A5 (https=) | ||
| JP2010532163A5 (https=) | ||
| CN106535917A (zh) | 用于抑制α‑1抗胰蛋白酶基因表达的组合物及方法 | |
| EP2701723B1 (en) | Dna aptamers for promoting remyelination | |
| BR0012938A (pt) | Método para a produzir um vìrus recombinante de caxumba, vìrus recombinante de caxumba, composição, método para imunizar um indivìduo, molécula de ácido nucleico, plasmìdeo, célula hospedeira, composição farmacêutica, e sequência de nucleotìdeos | |
| CN114555188A (zh) | 治疗apoc3相关疾病和病症的方法 | |
| JP2020522566A5 (https=) | ||
| JP2005511504A5 (https=) | ||
| HUP0104126A2 (hu) | Gyógyszer a csontmetabolizmus hibáira | |
| JP7846095B2 (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| US9650421B2 (en) | Self-assembled nanostructures | |
| JP2003512841A5 (https=) | ||
| ES2897248T3 (es) | Molécula de ácido nucleico con propiedades antiinflamatorias, anticoagulantes y organoprotectoras | |
| JP7237825B2 (ja) | 血中におけるｒｎａの安定性の改善剤および投与方法 | |
| TWI911432B (zh) | 含有多種多套胜肽的重組蛋白質、含有該重組蛋白質的醫藥組成物以及該重組蛋白質之製備方法 |